56433-01-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(Bromomethyl)-1-chloro-3-nitrobenzene is used as a key reactant in the synthesis of cyclic hydroxamic acid PF-04859989. 2-(bromomethyl)-1-chloro-3-nitrobenzene serves as a potent and selective inhibitor of human and rat Kynurenine aminotransferase II (KAT II), which is an enzyme involved in the metabolism of tryptophan. Inhibition of KAT II is a potential therapeutic strategy for the treatment of schizophrenia, as it may help regulate the levels of certain neurotransmitters in the brain.
Used in Chemical Research:
In addition to its pharmaceutical applications, 2-(bromomethyl)-1-chloro-3-nitrobenzene can be utilized in chemical research as a starting material for the development of new compounds with various potential applications. Its unique structure allows for further functionalization and modification, making it a valuable tool in the synthesis of novel molecules for a range of industries, including materials science, agrochemicals, and more.

InChI:InChI=1/C7H5BrClNO2/c8-4-5-6(9)2-1-3-7(5)10(11)12/h1-3H,4H2

Upstream product

• 83-42-1 6-chloro-2-nitrotoluene 
• 7726-95-6 bromine 
• 50907-57-8 (2-chloro-6-nitrobenzene)methanol 
• 88-72-2 1-methyl-2-nitrobenzene 

Downstream Products

• 89277-98-5 2-(2-chloro-6-nitrophenyl)acetonitrile 
• 56433-03-5 2-(6-Chlor-2-nitro-benzyl)-2-acetamino-malonsaeure-diethylester 
• 919076-97-4 acetate of 2-chloro-6-nitrobenzyl alcohol 
• 109319-74-6 N-(2-Chlor-6-nitrobenzyl)phthalimid 
• 85062-99-3 2,5-Dichloro-3-(4-methoxy-benzyl)-3,4-dihydro-quinazoline 
• 85062-92-6 5-chloro-3,4-dihydro-3-(p-methoxybenzyl)-2(1H)-quinazolinone 
• 85062-93-7 ethyl 5-chloro-3,4-dihydro-3-(p-methoxybenzyl)-2-oxo-1(2H)-quinazolineacetate 
• 81837-11-8 5-Chloro-3-(4-methoxy-benzyl)-3,4-dihydro-quinazolin-2-ylamine; hydrobromide 
• 85062-64-2 6-Chloro-4-(4-methoxy-benzyl)-4,5-dihydro-imidazo[1,2-a]quinazolin-2-one; hydrochloride 
• 85062-96-0 6-Chloro-4-(4-methoxy-benzyl)-3,3a,4,5-tetrahydro-2H-imidazo[1,2-a]quinazolin-1-one; hydrochloride 
• 85062-91-5 2-amino-6-chloro-4'-methoxydibenzylamine 
• 56433-11-5 6-Chlor-2-amino-phenylalanin 
• 56433-07-9 6-Chlor-2-nitro-phenylalanin 
• 97522-09-3 methyl 2-(2-chloro-6-nitrophenyl)acetate 

Relevant academic research and scientific papers

NOVEL FUNGICIDAL CARBAMATE COMPOUNDS

An object of the present invention is to provide a carbamate compound or a salt thereof that controls diseases. The present invention provides a carbamate compound represented by Formula (1), or a salt thereof, wherein R1, R3 and R6 are identical or different and each represents hydrogen, or the like; R2 represents hydrogen, halogen, or C1-6 alkyl; R4 and R5 are identical or different and each represents hydrogen, or the like; R7 represents hydrogen, or the like; R8 represents hydrogen, or C1-6 alkyl; X and Χ1 independently represent oxygen, or sulfur; Y represents oxygen, or sulfur; Z represents oxygen/ or sulfur; l is an integer of 0 to 2; m is an integer of 0 to 3; n is an integer of 0 to 4; and when l, m or n is more than one, the l, m or n may be the same or different.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R10, R11, R12, R13, R14, R15, R16, R17 and m are as described herein, compositions including the compounds and methods of using the compounds.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R15, R16, R17 and n are as described herein, compositions including the compounds and methods of using the compounds.

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

EP2/4 AGONISTS

EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).

METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS

The present invention relates to pyrimidine derivatives of Formula (Ia) and (Ib) (including tautomers, isomers, prodrugs, and pharmaceutically acceptable salts thereof). Said compounds are useful in the treatment of pain (such as neuropathic pain), inflammation, and epilepsy (by acting as anticonvulsants). Methods of medical treatment making use of said compounds, as well as additional compounds of Formula (IIa) and (IIb), are also disclosed.

Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors

Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that plays a critical role in the early development of the nervous system. Deregulation of CDK5 is believed to contribute to the abnormal phosphorylation of various cellular substrates associated with neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. Acyclic urea 3 was identified as a potent CDK5 inhibitor and co-crystallographic data of urea 3/CDK2 enzyme were used to design a novel series of 3,4-dihydroquinazolin-2(1H)-ones as CDK5 inhibitors. In this investigation we present our synthetic studies toward this series of compounds and discuss their biological relevance as CDK5 inhibitors.

Method for producing 2-halo-6-nitrobenzoic acids

The present invention relates to a process for the preparation of 2-halo-6-nitrobenzoic acids by oxidation of 2-halo-6-nitro-benzyl alcohols, esters, ethers, or mixtures thereof with nitric acid and to the use of this process as a step in the preparation of 2-halo-6-nitrobenzoic acids from 2-halo-6-nitrotoluenes.

2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use

Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

AMINE DERIVATIVES

A compound of the formula: ???whereinX and X' are the same or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or an amino optionally having substituents, and at least one of X and X' represents a fluorine atom, a chlorine atom or an amino optionally having substituents;R1 and R2 represent a hydrogen atom or C1-6 alkyl optionally having substituents, or R1 and R2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents;Y and Q are the same or different, and each represents a bond or a spacer having a main chain of 1 to 6 atoms;... represents a single bond or a double bond;T1 and T2 are the same or different, and each represents C(R9) (R9 represents a hydrogen atom, a hydroxy or C1-6 alkyl) or N, when each of the adjacent ... is a single bond, and C when the adjacent ... is a double bond; andAr represents an aromatic group optionally having substituents, a C3-9 cycloalkyl group optionally having substituents, a 3 to 9-membered saturated heterocyclic group optionally having substituents, a hydrogen atom or a halogen atom; provided that 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline; 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline and 1-benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide are excluded; a salt thereof or a prodrug thereof has an excellent somatostatin receptor binding inhibition action and is useful for preventing and/or treating diseases associated with somatostatin.